Arcadia Biosciences (NASDAQ:RKDA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report published on Thursday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.

Arcadia Biosciences Stock Down 0.7 %

Shares of NASDAQ:RKDA opened at $4.05 on Thursday. The company’s 50-day moving average price is $3.24 and its 200 day moving average price is $2.97. The company has a market cap of $5.51 million, a PE ratio of -0.81 and a beta of 1.27. Arcadia Biosciences has a fifty-two week low of $1.85 and a fifty-two week high of $5.34.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. The business had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. During the same quarter in the prior year, the firm posted ($2.64) earnings per share. As a group, equities analysts anticipate that Arcadia Biosciences will post -1.7 EPS for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.